View Financial HealthBio-Gate 配当と自社株買い配当金 基準チェック /06Bio-Gate配当金を支払った記録がありません。主要情報n/a配当利回り-14.6%バイバック利回り総株主利回り-14.6%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesReported Earnings • May 24Full year 2025 earnings releasedFull year 2025 results: Revenue: €8.22m (up 16% from FY 2024). Net loss: €1.16m (loss narrowed 28% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 2 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany.お知らせ • Aug 07Bio-Gate AG, Annual General Meeting, Sep 12, 2025Bio-Gate AG, Annual General Meeting, Sep 12, 2025, at 10:00 W. Europe Standard Time.New Risk • Sep 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€8.22m market cap, or US$9.06m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).お知らせ • May 09Bio-Gate AG, Annual General Meeting, Jun 14, 2024Bio-Gate AG, Annual General Meeting, Jun 14, 2024, at 10:00 W. Europe Standard Time.Reported Earnings • May 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €7.48m (up 22% from FY 2022). Net loss: €1.62m (loss narrowed 10% from FY 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.New Risk • Mar 28New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€9.24m market cap, or US$9.97m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding).New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€10.4m market cap, or US$11.4m).New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€2.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€8.49m market cap, or US$9.20m). Minor Risk Shareholders have been diluted in the past year (10.0% increase in shares outstanding).New Risk • Aug 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.74m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€8.74m market cap, or US$9.48m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€2.6m). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).Reported Earnings • Sep 08First half 2022 earnings released: EPS: €0 (vs €0.01 loss in 1H 2021)First half 2022 results: EPS: €0. Revenue: €2.75m (down 13% from 1H 2021). Net loss: €1.06m (loss widened €990.0k from 1H 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat.Reported Earnings • Apr 08Full year 2021 earnings releasedFull year 2021 results: Revenue: €6.52m (up 26% from FY 2020). Net loss: €544.1k (loss narrowed 32% from FY 2020). Over the next year, revenue is forecast to grow 17%, compared to a 8.9% growth forecast for the industry in Germany.決済の安定と成長配当データの取得安定した配当: BIG1の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: BIG1の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Bio-Gate 配当利回り対市場BIG1 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BIG1)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Chemicals)3.7%アナリスト予想 (BIG1) (最長3年)n/a注目すべき配当: BIG1は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: BIG1は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: BIG1の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: BIG1が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 04:34終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bio-Gate AG 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Cosmin FilkerGBC AGMatthias GreiffenbergerGBC AG
Reported Earnings • May 24Full year 2025 earnings releasedFull year 2025 results: Revenue: €8.22m (up 16% from FY 2024). Net loss: €1.16m (loss narrowed 28% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 2 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany.
お知らせ • Aug 07Bio-Gate AG, Annual General Meeting, Sep 12, 2025Bio-Gate AG, Annual General Meeting, Sep 12, 2025, at 10:00 W. Europe Standard Time.
New Risk • Sep 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€1.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.2m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (€8.22m market cap, or US$9.06m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).
お知らせ • May 09Bio-Gate AG, Annual General Meeting, Jun 14, 2024Bio-Gate AG, Annual General Meeting, Jun 14, 2024, at 10:00 W. Europe Standard Time.
Reported Earnings • May 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €7.48m (up 22% from FY 2022). Net loss: €1.62m (loss narrowed 10% from FY 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.
New Risk • Mar 28New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€9.24m market cap, or US$9.97m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding).
New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (€10.4m market cap, or US$11.4m).
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€2.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.3m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 16% per year over the past 5 years. Market cap is less than US$10m (€8.49m market cap, or US$9.20m). Minor Risk Shareholders have been diluted in the past year (10.0% increase in shares outstanding).
New Risk • Aug 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.74m (US$9.48m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (€8.74m market cap, or US$9.48m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€2.6m). Shareholders have been diluted in the past year (10.0% increase in shares outstanding).
Reported Earnings • Sep 08First half 2022 earnings released: EPS: €0 (vs €0.01 loss in 1H 2021)First half 2022 results: EPS: €0. Revenue: €2.75m (down 13% from 1H 2021). Net loss: €1.06m (loss widened €990.0k from 1H 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat.
Reported Earnings • Apr 08Full year 2021 earnings releasedFull year 2021 results: Revenue: €6.52m (up 26% from FY 2020). Net loss: €544.1k (loss narrowed 32% from FY 2020). Over the next year, revenue is forecast to grow 17%, compared to a 8.9% growth forecast for the industry in Germany.